

What is claimed is:

1. A method for treating inflammation in a subject which comprises administering to the subject soluble receptor
5 for advanced glycation endproduct (sRAGE) (SEQ ID NO:1) in an amount effective to treat inflammation in the subject.
2. A method for treating inflammation in a subject which
10 comprises administering to the subject a polypeptide consisting essentially of the V-domain (SEQ ID NO:2) of receptor for advanced glycation endproduct (RAGE) in an amount effective to treat inflammation in the subject.
- 15 3. A method for treating inflammation in a subject which comprises administering to the subject an agent in an amount which inhibits the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.
20
4. The method of claim 3, wherein the agent comprises a polypeptide, a peptidomimetic, an organic molecule, a carbohydrate, a lipid, an antibody or a nucleic acid.
- 25 5. The method of claim 4, wherein the polypeptide comprises an advanced glycation endproduct polypeptide or a portion thereof, a receptor for an advanced glycation endproduct polypeptide or a portion thereof, a soluble receptor for advanced glycation endproduct
30 polypeptide or a portion thereof.

6. The method of claim 4, wherein the antibody comprises an anti-RAGE antibody or an anti-RAGE F(ab')₂ fragment.
7. The method of any one of claims 1 to 3, wherein the
5 subject is a mammal.
8. The method of claim 7, wherein the mammal is a human.
9. The method of any one of claims 1 to 3, wherein the
10 administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, oral, anal, ocular or otic delivery.
- 15 10. The method of claim 3, wherein the agent is administered daily.
11. The method of any one of claims 1 to 3, wherein the
20 amount comprises a dose of from about 200 ng/day/kg body weight to about 200,000 ng/day/kg body weight.
12. The method of any one of claims 1 to 3, wherein the inflammation is associated with a wound in the subject.
- 25 13. The method of any one of claims 1 to 3, wherein the inflammation is associated with periodontal disease in the subject.
14. The method of any one of claims 1 to 2, wherein the
30 inflammation is associated with an autoimmune disease in the subject.

15. The method of claim 14, wherein the autoimmune disease is multiple sclerosis or autoimmune encephalitis.
- 5 16. The method of any one of claims 1 to 3, wherein the inflammation is associated with delayed-type hypersensitivity of a subject.
17. The method of any one of claims 1 to 3, wherein the
10 inflammation is associated with arthritis in a subject.
18. The method of claim 17, wherein the arthritis comprises collagen-induced arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, arthritis due to
15 Behchet's Syndrome, arthritis due to Sjogren's Syndrome, or arthritis induced by lupus.
19. The method of any one of claims 1 to 3, wherein the
20 inflammation is due to colitis in the subject.
20. The method of claim 19, wherein the colitis is ulcerative colitis.
21. The method of claim 19, wherein the colitis is due to
25 Crohn's disease.
22. The method of any one of claims 1 to 3, wherein the subject is suffering from an allergy.
- 30 23. The method of any one of claims 1 to 3, wherein the subject is suffering from asthma.

